Evidence map›Paper›PMID 39707452›Full record

ArticleWorld journal of surgical oncology2024

Surgery for patients with endometrioid-type endometrial cancer: is lymphadenectomy above the inferior mesenteric artery necessary?

Abdurrahman Alp Tokalioglu, Okan Oktar, Mehmet Unsal, Okan Aytekin, Baran Yesil, Huseyin Altas, Ayse Buran, Yesim Ucar, Dilek Yuksel, Gunsu Kimyon Comert and 8 more

Abstract read
In one paragraph

Article in World journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Abdurrahman Alp TokaliogluDepartment of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey. alptokalioglu@gmail.com.ORCID http://orcid.org/0000-0002-1776-2744
Okan OktarDepartment of Gynecologic Oncology, Ankara Etlik City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0002-9696-7886
Mehmet UnsalDepartment of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0002-9920-6804
Okan AytekinDepartment of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0002-6430-4607
Baran YesilDepartment of Gynecologic Oncology, Ankara Etlik City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0009-0000-4790-0880
Huseyin AltasDepartment of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0009-0003-3493-9411
Ayse BuranDepartment of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0002-8913-5846
Yesim UcarDepartment of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0002-1957-4202
Dilek YukselDepartment of Gynecologic Oncology, Ankara Etlik City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0002-2366-8412
Gunsu Kimyon ComertDepartment of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0003-0178-4196
Burak ErsakDepartment of Gynecologic Oncology, Ankara Etlik City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0003-3301-062X
Fatih KilicDepartment of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0002-7333-4883
Cigdem KilicDepartment of Gynecologic Oncology, Faculty of Medicine, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0002-4433-8068
Caner CakırDepartment of Gynecologic Oncology, Ankara Etlik City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0003-2559-9104
Sevgi KocDepartment of Gynecologic Oncology, Faculty of Medicine, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0002-1703-0690
Ozlem Moraloglu TekinDepartment of Obstetrics and Gynecology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0001-8167-3837
Yaprak UstunDepartment of Obstetrics and Gynecology, Faculty of Medicine, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0002-1011-3848
Taner TuranDepartment of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0001-8120-1143

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe primary objective of this study was to identify the risk of metastasis to lymph nodes above the inferior mesenteric artery (IMA) in endometrioid-type endometrial cancer (EC) and the factors that influence metastasis.

methodsThe study included patients who had been operated on for endometrioid-type EC in three gynecological oncology centers between 2007 and 2023. The supramesenteric lymph node (SM-LN) is the region between the left renal vein and the IMA, whereas the inframesenteric lymph node (IM-LN) is the region between the IMA and the aortic bifurcation, as determined by the level of the IMA.

resultsThe study sample comprised 412 patients. The median number of lymph nodes excised per patient was 58. The median count was 37 for pelvic lymph nodes, 21 for para-aortic lymph nodes, 8 for IM-LN, and 13 for SM-LN. In the univariate analysis, the factors that were found to be statistically significant in determining SM-LN metastasis included tumor size, depth of myometrial invasion, uterine serosal invasion, lymphovascular space invasion (LVSI), cervical invasion, peritoneal cytology, adnexal metastasis, omental metastasis, non-nodal extrauterine metastasis, pelvic lymph node metastasis, and IM-LN metastasis. In the multivariate analysis, SM-LN metastasis was independently associated with tumor size, LVSI, pelvic lymph node metastasis, and IM-LN metastasis.

conclusionIn conclusion, in cases of intermediate-high risk EC, it is important to know that the disease spreads to SM-LN in 7.3% of patients. The efficacy of postoperative adjuvant treatment may be inadequate due to a lack of information regarding the SM-LN region.

Indexed as

Carcinoma, EndometrioidEndometrial NeoplasmsLymphatic MetastasisLymph Node ExcisionLymph NodesMesenteric Artery, InferiorAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm InvasivenessPrognosisRetrospective StudiesEndometrial CancerInferior Mesenteric ArteryLymph Node Metastasis

Identifiers

PMID39707452
PMCPMC11662600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.